Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cutera, Inc. stock logo
CUTR
Cutera
$0.04
-63.9%
$0.04
$0.09
$1.87
$787K1.362.84 million shs27.70 million shs
Stereotaxis Inc. stock logo
STXS
Stereotaxis
$2.25
+0.4%
$2.15
$1.54
$2.72
$193.50M1.44335,424 shs182,759 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$112.46
-9.9%
$125.04
$55.00
$177.37
$3.80B2.061.37 million shs2.55 million shs
ViewRay, Inc. stock logo
VRAY
ViewRay
$0.34
$0.02
$4.96
$4.59M0.817.51 million shs108.50 million shs
Zynex Inc. stock logo
ZYXI
Zynex
$2.24
-2.6%
$2.31
$1.66
$10.62
$67.74M0.83174,736 shs106,163 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cutera, Inc. stock logo
CUTR
Cutera
0.00%0.00%0.00%0.00%-97.09%
Stereotaxis Inc. stock logo
STXS
Stereotaxis
+1.36%+1.82%-5.49%+34.94%+27.27%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-1.29%-3.06%-11.42%+54.85%-9.93%
ViewRay, Inc. stock logo
VRAY
ViewRay
0.00%0.00%0.00%0.00%0.00%
Zynex Inc. stock logo
ZYXI
Zynex
-3.77%-2.13%+5.02%+5.50%-74.39%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cutera, Inc. stock logo
CUTR
Cutera
N/AN/AN/AN/AN/AN/AN/AN/A
Stereotaxis Inc. stock logo
STXS
Stereotaxis
0.6026 of 5 stars
0.01.00.00.02.81.70.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.5214 of 5 stars
2.41.00.00.03.32.51.9
ViewRay, Inc. stock logo
VRAY
ViewRay
N/AN/AN/AN/AN/AN/AN/AN/A
Zynex Inc. stock logo
ZYXI
Zynex
1.8406 of 5 stars
3.20.00.00.00.61.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cutera, Inc. stock logo
CUTR
Cutera
2.50
Moderate Buy$3.007,592.31% Upside
Stereotaxis Inc. stock logo
STXS
Stereotaxis
0.00
N/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.80
Moderate Buy$127.3313.23% Upside
ViewRay, Inc. stock logo
VRAY
ViewRay
0.00
N/AN/AN/A
Zynex Inc. stock logo
ZYXI
Zynex
2.33
Hold$6.00167.86% Upside

Current Analyst Ratings Breakdown

Latest STXS, ZYXI, VRAY, CUTR, and TMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Zynex Inc. stock logo
ZYXI
Zynex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/17/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$130.00 ➝ $150.00
6/17/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/4/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.00
6/3/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.00
4/30/2025
Zynex Inc. stock logo
ZYXI
Zynex
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.00
4/30/2025
Zynex Inc. stock logo
ZYXI
Zynex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $8.00
4/29/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$90.00 ➝ $105.00
4/23/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cutera, Inc. stock logo
CUTR
Cutera
$155.21M0.01N/AN/A($8.62) per share0.00
Stereotaxis Inc. stock logo
STXS
Stereotaxis
$26.92M7.19N/AN/A$0.07 per share32.14
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$441.54M8.61$1.46 per share76.83$6.81 per share16.51
ViewRay, Inc. stock logo
VRAY
ViewRay
$105.86M0.00N/AN/A$0.45 per share0.00
Zynex Inc. stock logo
ZYXI
Zynex
$192.35M0.35$0.23 per share9.79$1.12 per share2.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cutera, Inc. stock logo
CUTR
Cutera
-$162.83M-$6.58N/AN/AN/A-84.86%N/A-45.07%8/6/2025 (Estimated)
Stereotaxis Inc. stock logo
STXS
Stereotaxis
-$24.05M-$0.28N/AN/AN/A-92.19%-325.86%-56.55%8/11/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.3682.6978.64N/A10.03%21.88%6.15%7/30/2025 (Estimated)
ViewRay, Inc. stock logo
VRAY
ViewRay
-$107.33M-$0.60N/AN/AN/A-104.30%-120.48%-42.39%N/A
Zynex Inc. stock logo
ZYXI
Zynex
$2.99M-$0.24N/A4.77N/A-4.30%-23.70%-6.23%7/23/2025 (Estimated)

Latest STXS, ZYXI, VRAY, CUTR, and TMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.48N/AN/AN/A$146.64 millionN/A
7/23/2025Q2 2025
Zynex Inc. stock logo
ZYXI
Zynex
-$0.20N/AN/AN/A$27.38 millionN/A
5/8/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29$0.70+$0.41$0.70$123.39 million$143.54 million
4/28/2025Q1 2025
Zynex Inc. stock logo
ZYXI
Zynex
-$0.24-$0.33-$0.09-$0.33$30.83 million$26.58 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cutera, Inc. stock logo
CUTR
Cutera
N/AN/AN/AN/AN/A
Stereotaxis Inc. stock logo
STXS
Stereotaxis
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
ViewRay, Inc. stock logo
VRAY
ViewRay
N/AN/AN/AN/AN/A
Zynex Inc. stock logo
ZYXI
Zynex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cutera, Inc. stock logo
CUTR
Cutera
N/A
2.88
1.86
Stereotaxis Inc. stock logo
STXS
Stereotaxis
N/A
1.07
0.66
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.92
9.10
8.32
ViewRay, Inc. stock logo
VRAY
ViewRay
N/A
1.16
0.91
Zynex Inc. stock logo
ZYXI
Zynex
2.87
3.46
2.63

Institutional Ownership

CompanyInstitutional Ownership
Cutera, Inc. stock logo
CUTR
Cutera
90.70%
Stereotaxis Inc. stock logo
STXS
Stereotaxis
45.35%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%
ViewRay, Inc. stock logo
VRAY
ViewRay
92.97%
Zynex Inc. stock logo
ZYXI
Zynex
29.68%

Insider Ownership

CompanyInsider Ownership
Cutera, Inc. stock logo
CUTR
Cutera
0.42%
Stereotaxis Inc. stock logo
STXS
Stereotaxis
17.77%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
ViewRay, Inc. stock logo
VRAY
ViewRay
2.50%
Zynex Inc. stock logo
ZYXI
Zynex
49.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cutera, Inc. stock logo
CUTR
Cutera
46020.19 million20.10 millionOptionable
Stereotaxis Inc. stock logo
STXS
Stereotaxis
13086.00 million70.72 millionNot Optionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21033.82 million31.46 millionOptionable
ViewRay, Inc. stock logo
VRAY
ViewRay
295183.40 million178.82 millionOptionable
Zynex Inc. stock logo
ZYXI
Zynex
77030.24 million15.34 millionOptionable

Recent News About These Companies

Zynex Shareholder Sues Board, Execs Over Insurer’s Payment Pause
Tricare Temporary Payment Suspension Update
Zynex (NASDAQ:ZYXI) Receives Buy Rating from HC Wainwright
Zynex appoints Steven Dyson as new CEO
Zynex taps Steve Dyson as chief executive officer
Zynex Announces Steven Dyson as New CEO
Zynex Announces Workforce Reduction
Here’s Why Zynex (ZYXI) Fell in Q1

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cutera stock logo

Cutera NASDAQ:CUTR

$0.04 -0.07 (-63.86%)
Closing price 03/12/2025
Extended Trading
$0.04 0.00 (0.00%)
As of 03/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Stereotaxis stock logo

Stereotaxis NYSEAMERICAN:STXS

$2.25 +0.01 (+0.45%)
Closing price 04:10 PM Eastern
Extended Trading
$2.23 -0.02 (-1.07%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$112.46 -12.32 (-9.87%)
Closing price 04:00 PM Eastern
Extended Trading
$112.50 +0.04 (+0.04%)
As of 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

ViewRay stock logo

ViewRay NASDAQ:VRAY

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.

Zynex stock logo

Zynex NASDAQ:ZYXI

$2.24 -0.06 (-2.61%)
Closing price 04:00 PM Eastern
Extended Trading
$2.24 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.